Dispatcher-assisted bystander CPR: a KISS for a kiss

++ – ? the patients with diabetes in VITAL, markers of systemic infl ammation, including C-reactive protein and tumour necrosis factor α, were not reduced. Diabetes is associated with aberrant shedding of megalin and cubilin, 9 the major endocytic transporters of fi ltered albumin in the proximal tubule (the megalin–cubilin complex). This retrieval pathway is also essential for the uptake of 25-hydroxy vitamin D3 and for its subsequent activation. Defi ciency or dysfunction of the megalin– cubilin complex decreases vitamin D concentrations and albuminuria. Importantly, this interaction seems to work both ways, because vitamin D also inhibits megalin shedding. Vitamin D might also induce the expression of nephrin, 10 a key component of the podocyte slit pore that

[1]  H. Parving,et al.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial , 2010, The Lancet.

[2]  M. Tokumoto,et al.  Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  N. Fujii,et al.  The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. , 2009, Bone.

[4]  S. Fishbane,et al.  Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  G. Cockrell,et al.  Microalbuminuria in Type 1 Diabetes Is Associated With Enhanced Excretion of the Endocytic Multiligand Receptors Megalin and Cubilin , 2009, Diabetes Care.

[6]  Zhongyi Zhang,et al.  Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. , 2008, Kidney international.

[7]  G. Ning,et al.  Renoprotective role of the vitamin D receptor in diabetic nephropathy. , 2008, Kidney international.

[8]  D. Batlle,et al.  Antiproteinuric effect of oral paricalcitol in chronic kidney disease. , 2005, Kidney international.

[9]  M. Wolf,et al.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.

[10]  Shu Q. Liu,et al.  1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .